Sun Pharma Advanced Research Co Intrinsic Value
Sun Pharma Advanced Research Co (SPARC) median intrinsic value is ₹648.69 from 7 valuation models (range ₹65–₹649), vs current price ₹216.23 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. Read Sun Pharma Advanced Research C dividend policy for the complete payout history and dividend yield track record.
SPARC Valuation Methods Summary — DCF, Graham Number & P/E
Sun Pharma Advanced Research Co intrinsic value across 7 models vs current price ₹216.23 — upside/downside and value range per method. Analyse Sun Pharma Advanced Research C shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹648.69 | ₹518.95 - ₹778.43 | +200.0% | EPS: ₹217.08, Sector P/E: 22x |
| Book Value Method | asset | ₹540.57 | ₹486.51 - ₹594.63 | +150.0% | Book Value/Share: ₹405.76, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹64.87 | ₹58.38 - ₹71.36 | -70.0% | Revenue/Share: ₹18.18, P/S: 2.0x |
| PEG Ratio Method | growth | ₹648.69 | ₹583.82 - ₹713.56 | +200.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹648.69 | ₹583.82 - ₹713.56 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹432.46 | ₹389.21 - ₹475.71 | +100.0% | ROE: 526.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹648.69 | ₹583.82 - ₹713.56 | +200.0% | EPS: ₹217.08, BVPS: ₹405.76 |
SPARC Intrinsic Value vs Market Price — All Valuation Models
Sun Pharma Advanced Research Co fair value range ₹65–₹649 vs current market price ₹216.23 across 7 valuation models. For current market price and key ratios, visit SPARC screener.
SPARC Intrinsic Value Analysis — Undervalued or Overvalued?
Sun Pharma Advanced Research Co median intrinsic value ₹648.69, current price ₹216.23 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of SPARC?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Sun Pharma Advanced Research Co (SPARC) is ₹648.69 (median value). With the current market price of ₹216.23, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹64.87 to ₹648.69, indicating ₹64.87 - ₹648.69.
Is SPARC undervalued or overvalued?
Based on our multi-method analysis, Sun Pharma Advanced Research Co (SPARC) appears to be trading below calculated value by approximately 200.0%.
SPARC Financial Health — Key Ratios vs Industry Benchmarks
Sun Pharma Advanced Research Co financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.87 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 526.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -506.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.03x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SPARC Cash Flow Quality — Operating & Free Cash Flow
Sun Pharma Advanced Research Co operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-239 Cr | ₹-251 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-360 Cr | ₹-360 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-429 Cr | ₹-429 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-69 Cr | ₹-343 Cr | Negative Cash Flow | 3/10 |